Department of Pediatrics, Eli & Edythe Broad Center of Regeneration Medicine & Stem Cell Research, University of California, San Francisco, CA 94143-1346, USA.
Regen Med. 2012 Sep;7(5):697-712. doi: 10.2217/rme.12.46.
Advances in directed differentiation of human embryonic stem cells (hESCs) toward cardiac lineages have generated much interest within the myocardial therapy field. Beyond the promise that hESCs would provide a supply of new cardiomyocytes to the damaged heart, recent studies have also shown that paracrine effects of stem cell therapy may facilitate myocardial healing. This review describes the advantages of hESCs for these purposes, current methods for directing differentiation of hESCs toward cardiac fates, approaches to purification and engineered selection of hESC-derived cardiomyocytes and cardiac precursors, as well as animal studies that have shed light on the therapeutic uses of hESCs in cardiac regenerative medicine.
人胚胎干细胞（hESC）向心脏谱系的定向分化方面的进展在心肌治疗领域引起了广泛关注。除了 hESC 有望为受损心脏提供新的心肌细胞供应这一前景外，最近的研究还表明，干细胞治疗的旁分泌作用可能促进心肌愈合。本文综述了 hESC 在这些方面的优势、目前将 hESC 定向分化为心脏命运的方法、hESC 衍生的心肌细胞和心脏前体细胞的纯化和工程选择方法，以及阐明 hESC 在心脏再生医学中的治疗用途的动物研究。
